Last reviewed · How we verify
Clostridium difficile
At a glance
| Generic name | Clostridium difficile |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology (NA)
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Fecal Microbiota Transplant (PHASE4)
- VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE3)
- FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach (PHASE1, PHASE2)
- Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |